Search

Abstract Background CRC is one of the most common malignancies worldwide, and its molecular mechanisms remain unclear. Elevated levels of BAG3 have been reported in various tumors. The present study aimed to explore the expression and function of BAG3 in CRC. Methods BAG3 protein expression was evaluated in 90 CRC specimens using immunohistochemistry in tissue microarrays, and the correlation between BAG3 expression and the clinicopathological features were assessed. In HCT116 cells BAG3 overexpression cell models were constructed, and CRISPR/Cas9 was used for BAG3 knockout. Western blotting and quantitative real-time PCR were used to determine BAG3 expression in HCT-116 Cells. Cell proliferation, migration and invasion were analyzed by cell counting, colony formation assay, EdU cell proliferation assay, RTCA growth curve assays, wound-healing migration assay and transwell invasion assay. The influence of BAG3 expression level on chemoresistance in HCT-116 cells was examined. Gene expression microarray and IPA analyses were employed to explore signaling pathways associated with the control of BAG3. Results Using immunohistochemistry, this study found that BAG3 was markedly upregulated in colorectal cancer tissues and that BAG3 levels were significantly associated with tumor size and gender. BAG3 overexpression promoted HCT-116 cell growth, migration and invasion in vitro. In contrast, BAG3 knockout inhibited HCT-116 cell growth, migration and invasion. HCT-116 cells with high expression of BAG3 had higher cell viability and lower apoptosis rate than control cells after treatment with 5-FU, while the BAG3 knockout group demonstrated the opposite effects. So BAG3 expression level was associated with chemoresistance to 5-FU in HCT-116 cells. Gene expression microarrays and bioinformatics analyses of HCT-116 cells with BAG3 knockout demonstrated the involvement of BAG3 in signaling pathways associated with the control of cell proliferation, migration, invasion and chemoresistance in CRC. Conclusions In conclusion, this study provided evidence that BAG3 has a relevant role in CRC biology, and defined potential molecular pathways and networks. So BAG3 may be considered as a potential therapeutic target for anti-tumor therapy in colorectal cancer.

The aim of the present study was to perform the accurate prognosis of different molecular types breast cancer (BC) by using the partitioning calculation method of the Ki-67 index. Partitioning calculation was used to judge the Ki-67 index and the molecular type was classified according to the 2019 Chinese Society of Clinical Oncology guidelines in 199 cases of BC. The association between the Ki-67 index and overall survival (OS), disease-free survival (DFS) and molecular types was analyzed using the Chi-squared test. Survival analysis was performed using the Kaplan-Meier method with statistical SPSS 18.0 software. The results revealed that the 5-year survival rate of patients with BC was 18.60% (8/43), the 6-year survival rate was 38.24% (26/68), while the 10-year survival rate of patients with BC was 73.08% (133/182); the results indicated that almost 80% patients succumbed during the 5 years following diagnosis. Marked differences were found between the OS of patients with BC and the Ki-67 index (between 50 to 54%) (χ2=4.83, P=0.028; χ2=4.60, P=0.032 respectively). All 14 cases of luminal A subtype BC with a Ki-67 index ≤4% survived at the end of follow-up time (69-156 months). At the same time, there was a marked difference between two groups of patients with overexpression HER-2 while using 50% as a cut-off point of Ki-67 (χ2=5.54, P=0.019). On the whole, the present study demonstrates that the partitioning calculation of the Ki-67 index can be used to judge the prognosis of patients with BC accurately. The prognosis of patients with different molecular subtypes of BC may be associated with the different Ki-67 index. [ABSTRACT FROM AUTHOR]